Sandra Porcile Rojas-Caro
Direktor/Vorstandsmitglied bei RIPLEY CORP S.A.
Aktive Positionen von Sandra Porcile Rojas-Caro
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| RIPLEY CORP S.A. | Direktor/Vorstandsmitglied | 01.01.2020 | - |
| Independent Dir/Board Member | 01.01.2020 | - |
Karriereverlauf von Sandra Porcile Rojas-Caro
Ehemalige bekannte Positionen von Sandra Porcile Rojas-Caro
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| NEUBASE THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 24.05.2021 | 28.10.2022 |
| GEMI THER | Technik-/Wissenschafts-/F&E-Leiter | - | - |
| SPYRE THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 16.05.2016 | - |
| SYNAGEVA BIOPHARMA CORP | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2013 | - |
Ausbildung von Sandra Porcile Rojas-Caro
| Pontificia Universidad Católica de Chile | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| Chile | 3 |
Operativ
| Chief Tech/Sci/R&D Officer | 4 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 2 |
| Retail Trade | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| NEUBASE THERAPEUTICS, INC. | Health Technology |
| RIPLEY CORP S.A. | Retail Trade |
| Private Unternehmen | 2 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
